TABLE 5.
Baseline Immunosuppression and Changes While on Therapy
| METAVIR | METAVIR | ||
|---|---|---|---|
| F0-F2 (n 5 38) | F3-F4 (n 5 23) | P Value | |
| Tacrolimus monotherapy | 23 (60.5) | 14 (60.9) | — |
| Tacrolimus/MMF | 9 (23.7) | 5 (21.7) | — |
| Tacrolimus dose reduction | 11 (28.9) | 1 (4.3) | 0.007 |
| Tacrolimus dose increased | 0 | 3 (13) | |
| Cyclosporine/MMF | 2 (5.3) | 1 (4.3) | — |
| mTOR monotherapy | 2 (5.3) | 1 (4.3) | — |
| mTOR/MMF | 2 (5.3) | 2 (8.7) | — |
| mTOR dose reduction | 1 (2.6) | 0 | — |
NOTE: Data are given as n (%).